Jabbit

News explainer · Sources checked October 15, 2026

Published · Updated

Hims & Hers drops compounded “Wegovy pill” plan after FDA warning

On March 9, 2026, the Los Angeles Times reported that Hims & Hers abandoned its plan for a cheaper compounded alternative to Wegovy after an FDA warning.[1]

The FDA statement behind it

A month earlier, FDA said it intended to restrict GLP-1 active ingredients for non-approved compounded drugs mass-marketed as similar alternatives to approved drugs, and named Hims & Hers specifically.[2]

What companies cannot claim

FDA said promotional materials cannot call non-approved compounded products generic versions of, or the same as, approved drugs, and cannot claim they are clinically proven to produce results.[2] Its March 2026 telehealth warning letters focused on the same issues.[3]

References

  1. Los Angeles Times. Hims & Hers abandons plan for cheaper Wegovy knockoff after FDA warning. March 9, 2026. https://www.latimes.com/business/story/2026-03-09/hims-hers-abandons-plan-for-cheaper-wegovy-knockoff-after-fda-warning. Checked October 15, 2026.
  2. U.S. Food and Drug Administration. FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs. Statement, February 6, 2026. https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs. Checked October 15, 2026.
  3. U.S. Food and Drug Administration. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. Press announcement, March 3, 2026. https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s. Checked October 15, 2026.

This page summarizes published research and regulatory documents. It is not medical advice and does not recommend starting, stopping, or changing any medication.